CURRICULUM VITAE
DENNIS F. MOORE, JR., M.D., F.A.C.P.

Office Address: 818 N. Emporia, Ste, 403
Wichita, KS 67214

Office Phone: (316) 262-4467 / Fax: (316) 262-0706

Present Position: Physician, Cancer Center of Kansas
Date of Hire: 07/01/94

Medical Licensure: 1990, State of Kansas

Languages Spoken: English, Spanish, French, Italian, Swahili, Wolof

EDUCATION:

Year	Degree	Institution
8/1979-5/1982	--	Washington University, St. Louis, Missouri
8/1982-5/1983	B.A.	University of Kansas, Lawrence, Kansas
8/1983-5/1987	M.D.	University of Kansas School of Medicine, Kansas City, Kansas

POSTGRADUATE EDUCATION:

Year	Degree	Institution
1987-90	Resident, Internal Medicine	Baylor College of Medicine, Houston, Texas
1990-93	Fellow, Medical Oncology	University of Texas, M.D. Anderson Cancer Center and Hematology, Houston, Texas
7-12/1991	Fellow, Hematology	Baylor College of Medicine, Houston, Texas

ACADEMIC APPOINTMENTS:

Month & Year	Position	Institution
7/1/04	Clinical Professor of Medicine	University of Kansas School of Medicine Wichita, Kansas
7/1/99	Clinical Associate Professor	University of Kansas School of Medicine Wichita, Kansas
7/1996 to 6/1998	Clinical Assistant Professor	University of Kansas School of Medicine Wichita, Kansas
7/1994 to 6/1996	Assistant Professor	University of Kansas School of Medicine Wichita, Kansas
7/1994	Adjunct Assistant Professor of Medicine	University of Texas, M.D. Anderson Cancer Center, Houston, Texas
7/1993 to 6/1994	Assistant Professor & Assistant Internist	University of Texas, M.D. Anderson Cancer Center, Houston, Texas
11/1991 to 6/1993	Junior Faculty Associate	University of Texas, M.D. Anderson Cancer Center, Houston, Texas

CERTIFICATIONS:

Board	Date	Recertification
American Board of Internal Medicine	9/1991	Current
Subspecialty (ABIM) Medical Oncology	11/1993	Current
Subspecialty (ABIM) Hematology	11/1996	Current

PROFESSIONAL SOCIETIES AND AFFILIATIONS: (INCLUDING OFFICES HELD)

Year	Organization	Office
2022-Current	Samaritan's Purse, Togo, West Africa	Medical Staff Volunteer
2019- Current	Cancer Research of Kansas	Participating Physician
2014-Current	Medical Society of Sedgwick County *Ethics Committee*	Member
2009-10	Wesley Medical Center Internal Medicine	Exec. Committee
2006	Kansas Chapter of American Society of Clinical Oncology	President
2004	Journal of Rheumatology	Reviewer
1999	American College of Physicians	Fellow
1999-Current	American Society of Internal Medicine	
1999-Current	Texas Society of Internal Medicine	
1999-Current	American Society of Hematology	
1999-Current	American Society of Clinical Oncology	
1999-Current	American Society for Blood and Marrow Transplantation	
1999-Current	Kansas Society of Clinical Oncology	
1997	International Society for Hematotherapy and Graft Engineering	Secretary
1994	National Cancer Institute (NCI)	
1994	M.D. Anderson	
1994	University of Rochester	
1994-Current	National Surgical Adjuvant Breast & Bowel Project (NSABP)	
1994-2019	Wichita Community Clinical Oncology Program (WCCOP)	Board Member
1994-Current	Leukemia Society of America (Kansas Chapter)	Past President and Board Member
1994-Current	Southwest Oncology Group (SWOG)	
1999-Current	Blood and Marrow Transplant Program	

OTHER AFFILIATIONS:

Organization
Catholic Ministries Winnebago-Omaha Nation in Nebraska
National Rifle Association
St. Vincent de Paul Catholic Church, Homeless Outreach
St. Anthony Family Shelter
Samaritan's Purse- West Africa

NON-PROFIT AFFILIATIONS THROUGH CANCER CENTER OF KANSAS SPONSORSHIP:

Organization
American Cancer Society
The Lord's Diner
Leukemia and Lymphoma Society
Victory in the Valley
Wichita Grand Opera

Wichita Cancer Foundation
Music Theatre of Wichita
Kidzcope
Young Life
Wichita Children's Home
Sedgwick County Zoo
Disabled American Veterans
YMCA
St. Jude Children's Research Hospital
ASPCA
Wounded Warrior
Kansas Humane Society
Kansas Food Bank
Victory in the Valley
Class LTD

HONORS AND AWARDS:

Year	Organization
	Best Doctors in America – Recognition by Wichita Business Journal
2015-2016	Best Doctor
	National Cancer Institute
2011, 2016	Platinum Award for ≥ 25 Patients in total accruals in NCI/Cancer Control Clinical Trials
2011	Plaque received for 2nd highest enrollment of patients in the US on NCI Treatment and Cancer Control Clinical Trials (WCCOP Award).
	Via Christi Regional Medical Center
9/2005	St. Luke Physician Recognition Award for the core value of Human Dignity
4/2004	**Loyal Order** of **the Moose**
	Washington University, St. Louis, Missouri
1981-82	President, Xi Chapter of Tau Kappa Epsilon
1983-87	**University of Kansas School of Medicine**
	Summer Research Fellowship
	Nell Educational Trust Scholarship
1987	**Cieneguilla, Peru**
	St. Francis Award, Parroquia de Cieneguilla
	American Cancer Society
1990-91	Junior Investigator Award
1992-93	Research Fellowship
	University of Texas, M.D. Anderson Cancer Center
1990-91	Clifton D. Howe Award for Excellence in Clinical Oncology
1991-92	Competitive Research Award
1991-92	Sandoz Research Fellow Award (Dept. Hematology)
1992-93	Competitive Research Award
6/9/1993	Outstanding Chief Fellow (Special Award)
	Schwachmann Syndrome Foundation and Registry
4/1995-	Advisory Board

Leukemia Society of America

8/1997	Dr. Dennis Moore, Sr. Award
2/2001-	Preferred Health Systems Specialty Advisory Board
5/2004	Clinical Professor – KU School of Medicine

RESEARCH ACTIVITIES:

1. Brief statement of area of research interest:
   a. Lymphoma, hematologic malignancies and stem cell transplantation
2. Current Projects Underway:
   a. Completing work on lymphoma booklet
   b. Analyzing and writing manuscript for Phase II Lymphoma Trial for SWOG
   c. Collaborating with colleagues at MD Anderson Cancer Center to complete manuscripts regarding original observations in patients with lymphoma.
3. Grant Support Available:
   a. Previous grants
   b. American Cancer Society (1990-91, $10,000)
   c. Competitive Research Award, University of Texas MD Anderson Cancer Center: 1991-92, $3,300.
   d. Sandoz Research Fellow Award: 1991-92, $30,000.
   e. Competitive Research Award, University of Texas MD Anderson Cancer Center: 1991-92, $3,500.
   f. American Cancer Society Research Fellowship: 1992-93, $3,600.

CLINICAL ACTIVITIES:

Dr. Moore spends more than 80 hours per week in patient care.

TEACHING ACTIVITIES:

Fall 1994	Oncologic Emergencies, Junior Tutorial
Spring 1995	Oncologic Emergencies, Junior Tutorial - 3 sessions
Fall 1995	Oncologic Emergencies, Junior Tutorial - 3 sessions
Spring 1996	Oncologic Emergencies, Junior Tutorial - 3 sessions
Fall 1996	Oncologic Emergencies, Junior Tutorial - 3 sessions
Spring 1997	Oncologic Emergencies, Junior Tutorial - 3 sessions
Fall 1997	Oncologic Emergencies, Junior Tutorial - 3 sessions
Spring 1998	Oncologic Emergencies, Junior Tutorial - 3 sessions
Spring 1995	4 months Resident Oncology Attending
Fall 1995	2 months Resident Oncology Attending
Spring 1996	5 months Resident Oncology Attending
Fall 1996	4 months Resident Oncology Attending
Spring 1997	3 months Resident Oncology Attending
Fall 1997	3 months Resident Oncology Attending
Spring 1998	5 months Resident Oncology Attending
Fall 1998	4 months Resident Oncology Attending
Spring 1997	7 lectures for Residents' Core Curriculum Series
1994- Current	Hematology/ Oncology Attending Physician with University of Kansas Medical School - Wichita

ADMINISTRATION:

Dates	**Organization**

University of Kansas School of Medicine

1985	Multidisciplinary Cancer Committee Representative
1984-85	Medical Students' Assembly
1984-85	Blood Drive-Hepatavax Information Committee
1984-86	Jayhawker MD Yearbook Committee

University of Kansas School of Medicine-Wichita

1986-87	Community Relations Committee Representative
1986-87	Research Committee

University of Texas, M.D. Anderson Cancer Center

1992-93	Chief Fellow
1993-94	Lymphoma Section Clinic Liaison to Office of Managed Care
1993-94	Clinic Chief, Section of Lymphoma
1993-94	Committee on Managed Care
1993-94	Ad Hoc Committee on Marketing
1994	Alternate, Physician Advisor for Section of Bone Marrow Transplantation

PUBLISHED MANUSCRIPTS:

1. Moore D: The Importance of the Monocyte in Patients with Breast Cancer. *1984 Medical Student Research Training Program*, KUMC 1984 Fall; 5: 296-323.
2. Pazdur R, Bready B, Moore DF Jr: Clinical Trials of Fluorouracil with Alpha-Interferon in Advanced Colorectal Carcinomas. *Semin Oncol* 1991 October; 18 (5 Suppl 7):67-70.
3. Pazdur R, Moore DF Jr, Bready B: The Modulation of Fluorouracil with Recombinant Alpha Interferon: The M.D. Anderson Clinical Trial. *Semin Oncol* 1991; 18 (Suppl 7):67-70.
4. Pazdur R, Moore D, Bready B: Modulation of Fluorouracil with Recombinant Alpha Interferon: M.D. Anderson Clinical Trial. *Semin Oncol* 1992; 19 (2 Suppl 3):176-179.
5. Moore DF Jr, Pazdur R, Daugherty K, Tarassoff P, Abbruzzesse JL: Phase II Study of Gemcitabine in Advanced Colorectal Carcinoma. *Invest New Drugs* 1992 Nov; 10(4):323-325.
6. Moore DF Jr, Pazdur R: Phase I Study of 5-Fluorouracil with Folinic Acid Combined with Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor. *Am J Clin Oncol* 1992 Dec; 15(6):464-466.
7. Pazdur R, Newman RA, Newman BM, Fuentes A, Benvenuto J, Bready B, Moore D, Jaiyesimi I, Vreeland F, Raber MN: Phase I Trial of Taxotere (RP 56976, NSC 628503): Five-day Schedule. *J Natl Cancer Inst* 1992; 84:1781-1788.
8. Moore D, Pazdur R: Systemic Therapies for Unresectable Primary Hepatic Tumors. *J Surg Oncol* 1993; 3(Suppl):112-114.
9. Moore DF Jr, Cabanillas F: What Constitutes a 'Cure' in Lymphoma? *Leuk Lymphoma* 1993; 11(3-4):161-163.
10. Moore DL Jr, Sears DA: Pica, Iron Deficiency, and the Medical History. *Am J Med* 1994; 97:390-393.
11. Moore DF, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL 3rd, Belt RJ, Mangold C, Bready B, Winn RJ: Phase II Trial of Edatrexate in Patients with Advanced Pancreatic Adenocarcinoma. *Ann Oncol* 1994 Mar; 5(3):286-287.
12. Pazdur R, Moore DF, Bready B, Giannone L, Maldonado A, Lin YG, Fueger RH, Winn RJ, Levin B: Phase II Trial of Edatrexate in Patients with Advanced Hepatocellular Carcinoma. *Ann Oncol* 1994 Sept; 5(7):646-648.

13. Moore DF Jr, Pazdur R, Abbruzzese JL: A Phase II Trial of Intravenous Melphalan in Advanced Colorectal Carcinoma. *Invest New Drugs* 1994; 12:133-136.

14. Moore DF, Kalvakolanu DV, Lippman SM, Kavanagh JJ, Hong WK, Borden EC, Paredes-Espinoza M, Krakoff IH: Retinoic Acid and Interferon in Human Cancer: Mechanistic and Clinical Studies. *Semin Hematol* 1994; 31(Suppl 5):31-37.

15. Romaguera JE, Rodriguez MA, Hagemeister FB, McLaughlin P, Swan F, Moore DF Jr, Sarris AH, Younes A, Hill D, Cabanillas F: A Phase II Trial of Oral Etoposide with Mitoxantrone and Ifosfamide/Mesna Consolidated with Intravenous Etoposide, Methylprednisolone, High-dose Arabinoside, and Cisplatin as Salvage Therapy for Relapsing and/or Refractory Lymphomas. *Invest New Drugs* 1994; 12(3):217-222.

16. Romaguera JE, Sarris AH, Swan F Jr, Younes A, Hagemeister FB, McLaughlin P, Rodriguez MA, Moore DF Jr, Cabanillas F: Phase II Study of Protracted 5-Fluorouracil Infusion in Patients with Relapsing or Refractory Lymphoma. *J Infus Chemother* 1994; 4:173-176.

17. Moore DF Jr, Buescher S, Vadhan-Raj S: Interleukin-1 Alpha Administration Increases Oral Granulocytes and Epithelial Cells. *J Infect Dis* 1994; 169(6):1419-1420.

18. Duvic M, Moore D, Menter A, Vonderheid EC: Cutaneous T Cell Lymphoma in Association with Silicone Breast Implants and Polyurethane: A Report of Four Cases. *J Am Acad Dermatol* 1995 Jun; 32(6):939-942.

19. Moore DF Jr, Moulopoulos LA, Dimopoulos MA: Waldenstrom Macroglobulinemia Presenting as a Renal or Perirenal Mass: Clinical and Radiographic Features. *Leuk Lymphoma* 1995 Apr; 17(3-4):331-334.

20. Younes A, Sarris A, Melnyk A, Romaguera J, McLaughlin P, Swan F, Rodriguez A, Hagemeister F, Moore D, North L, Smith TL, Cabanillas F: Three Hour Paclitaxel Infusion in Patients with Refractory and Relapsed Non-Hodgkin's Lymphoma. *J Clin Oncol* 1995; 13(3):583-587.

21. Moore DF Jr, Vadhan-Raj S: Sustained Response in Felty's Syndrome to Prolonged Administration of Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor (rhGM-CSF). *Am J Med* 1995; 98(6):591-594.

22. Moore DF Jr, Pazdur R, Sugarman S, Jones D 3rd, Lippman SM, Bready B, Abbruzzese JL: Pilot Phase II Trial of 13-*Cis*-Retinoic Acid and Interferon-as Combination Therapy in Advanced Pancreatic Adenocarcinoma. *Am J Clin Oncol* (CCT) 1995 Dec; 18:(6):525-527.

23. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Mansfield P, Callendar D, Mesina O, Cabanillas F: Cyclosporin A Does Not Reverse Clinical Resistance to Paclitaxel in Patients with Relapsed Non-Hodgkin's Lymphoma. *J Clin Oncol* 1996; 14(1):233-239.

24. Beran M, Kantarjian H, O'Brien S, Koller C, Al-Bitar M, Arbuck S, Pierce S, Moore D, bburzzese JL, Andreeeff M, Keating M, Estey E: Topotecan, a Topoisomerase-1 Inhibitor, is Active in the Treatment of Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia. *Blood* 1996; 88:2473-2479.

25. Van Besien KW, de Lima M, Giralt SA, Moore DF Jr, Khouri IF, Rondon G, Mehra R, Andersson BS, Dyer C, Clearly K, Przepiorka D, Gajewski JL, Champlin RE: Management of Lymphoma Recurrence After Allogeneic Transplantation: The Relevance of Graft Versus Lymphoma Effect. *Bone Marrow Transplant* 1997 May; 19(10):977-982.

26. Reddy SP, Harwood RM, Moore DF, Grimm EA, Murray JL, Vadhan-Raj S: Recombinant Interleukin-2 in Combination with Recombinant Interferon-γ in Patients with Advanced Malignancy: A Phase 1 Study. *J Immunother* 1997; 20(1):79-87.

27. Moore DF Jr, Cabanillas F: Staging and Prognostic Factors in Non-Hodgkin's Lymphoma. *Oncology* 1998 Oct; 12(10 Suppl 7):1-8.

28. Moore DF Jr, Cabanillas F: Overview of Prognostic Factors in Non-Hodgkin's Lymphoma. *Oncology* 1998; 12(10 Suppl 8):17-24.

29. Weiss GR, Liu PY, Alberts DS, Peng YM, Fisher E, Xu MJ, Scudder SA, Baker LH, Moore DF, Jr., Lippman SM: 13-Cis-Retinoic Acid or All-Trans-Retinoic Acid Plus Interferon-α in Recurrent Cervical Cancer: A Southwest Oncology Group Phase II Randomized Trial. *Gynecol Oncol* 1998:71:386-390.

30. Pazdur R, Medgyesy DC, Dakhil SR, Moore DF Jr, Scalzo A, Hoff PM, Arbuck SG, Abbruzzese JL: Phase II Trial of 9-Aminocamptothecin (NSC 603071) Administered as a 120-Hour Continuous Infusion Weekly for Three Weeks in Metastatic Colorectal Carcinoma. *Invest New Drugs* 1999; 16(4):341-346.

31. Samlowski WE, LeBlanc M, Kuebler PJ, Mandanas RA, Mangan KF, Moore DF Jr, Schuller DE, Ensley JF: Evaluation of Tomudex in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Southwest Oncology Group Study. *Invest New Drugs* 1999; 16(3):271-274.

32. Moore DF Jr., Brown TD, LeBlanc M, Dahlberg S, Miller TP, McClure S, Fisher RI: Phase II Trial of Menogaril in Non-Hodgkin's Lymphomas: A Southwest Oncology Group Trial. *Invest New Drugs* 1999; 17(2):169-172.

33. Poplin EA, Liu PY, Delmore JE, Wilczynski S, Moore DF Jr, Potkul RK, Fine BA, Hannigan EV, Alberts DS: Phase II Trial of Oral Etoposide in Recurrent or Refractory Endometrial Adenocarcinoma: A Southwest Oncology Group Study. *Gynecol Oncol* 1999; 74(3):432-435.

34. Hesketh PJ, Crowley JJ, Burris HA III, Williamson SK, Balcerzak SP, Peereboom D, Goodwin JW, Gross HM, Moore DF Jr, Livington RB, Gandara DR: Evaluation of Docetaxel in Previously Untreated Extensive-Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial. *The Cancer J from Scientific American* 1999; 5(4):237-241.

35. Macdonald JS, Jacobson JL, Modiano M, Moore DF Jr, Gandara DR, Schoder LE, Chapman RA: A Phase II Trial of Etoposide, Leucovorin, 5-FU, and Interferon Alpha 2b (ELFI) + G-CSF for Patients with Pancreatic Adenocarcinoma: A Southwest Oncology Group Study (SWOG-9413). *Invest New Drugs* 2000; 18:269-273.

36. Chauncey TR, Rankin C, Anderson JE, Chen I, Kopecky KJ, Godwin JE, Kalaycio ME, Moore DF Jr, Shurafa MS, Petersdorf SH, Kraut EH, Leith CP, Head DR, Luthardt FW, Willman CL, Appelbaum FR: A Phase I Study of Induction Chemotherapy for Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Mitoxantrone, Etoposide, and MDR Modulator PSC833: A Southwest Oncology Group Study 9617. *Leukemia Research* 2000; 24:567-574.

37. Siefker-Radtke AO, Millikan RE, Tu SM, Moore DF Jr, Smith TL, Williams D, Logothetis CJ: Phase III Trial of Fluorouracil, Interferon Alpha-2b, and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Metastatic or Unresectable Urothelial Cancer. *J Clin Oncol* 2002 Mar; 20(5):1361-1367.

38. Weick JK, Crowley JJ, Hussein MA, Moore, DF, Barlogie B: The Evaluation of Gemcitabine in Resistant or Relapsing Multiple Myeloma, Phase II: A Southwest Oncology Group Study. *Invest New Drugs* 2002 Feb; 20(1):117-121.

39. Saad ED, Kraut EH, Hoff PM, Moore DF Jr, Jones D, Pazdur R, Abbbruzzese JL: Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer. *Am J Clin Oncol* 2002 Oct; 25(5):451-453.

40. Alberts SR, Townley PM, Goldberg RM, Cha SS, Moore, DFJ, Krook JE, Buckner JC, Fitch TR, Wiesenfeld M, Mailliard JA: Gemcitabine and Oxaliplatin for Metastatic Pancreatic Cancer: A North Central Cancer Treatment Group (NCCTG) Phase II Study. *Ann Oncology* 2002 Apr; 13(4):553-557.

41. Roscoe JA, Morrow GR, Hickok JT, Bushunow PW, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr, Atkins JN: The Efficacy of Acupressure and Acustimulation Wrist Bands for the Relief of Chemotherapy-Induced Nausea and Vomiting: A URCC CCOP Multicenter Study. *J Pain Symptom Management* 2003 Aug; 26(2):731-742.

42. Goyle KK, Moore DF Jr, Garrett C, Goyle V: Benign Metastasizing Leiomyomatosis: Case Report and Review. *Am J Clin Oncol* 2003 Oct; 26(5):473-476.

43. Hofman M, Morrow GR, Roscoe JA, Hickok JT, Mustian KM, Moore DF, Wade JL, Fitch TR: Cancer Patients' Expectations of Experiencing Treatment-Related Side Effects. A University of Rochester Cancer Center Community Clinical Oncology Program Study of 938 Patients from Community Practices. *Cancer* 2004 Aug; 101(4):851-857.

44. Alberts SR, Schroeder M, Erlichman C, Steen PD, Foster NR, Moore DF, Rowland KM, Nair S, Tschetter LK, Fitch TR: Gemcitabine and ISIS-2503 for Patients with Locally Advanced or Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Trial. *J Clin Oncol* 2004 Dec 15; 22(24):4944-4950.

45. Loprinzi CL, Levitt R, Barton DL, Sloan JA, Atherton PJ, Smith DJ, Dakhil SR, Moore Jr DF, Krook JE, Rowland KM, Mazurczak MA, Berg AR, Kim GP: Evaluation of Shark Cartilage in Patients with Advanced Cancer: A North Cancer Clinical Trial Group Trial. *Cancer* 2005 Jul 1; 104(1):176-182.

46. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Hillard M, Lazarus HM, Hurd DD, McCoy J, Moore DF, Dakhil SR, Lanier KS, Chapman RA, Cromer JN, Salmon SE, Durie B, Crowley JC: Standard Chemotherapy Compared with High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321. *J Clin Oncol* 2006 Feb 23; 24(6):929-936. Epub 2006 Jan 23. Erratum in *J Clin Oncol* 2006 Jun 10; 24(17):2687. Moore, Dennis F Jr (added).

47. Haddock MG, Swaminathan R, Foster NR, Alberts SR, Hauge MD, Martenson JA, Fitch TR, Stella PJ, Tenglin RC, Schaefer PL, Moore DF, Dakhil SR: Gemcitabine, Cisplatin and Radiation Therapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Study, N9942. *J Clin Oncol* 2007 Jun 20; 25(18):2567-2572.

48. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF, Kozelsky TF, Jett JR: Phase I North Central Cancer Treatment Group Trial-N9923 of Escalating Doses of Twice-Daily Thoracic Radiation Therapy with Amifostine and with Alternating Chemotherapy in Limited Stage Small-Cell Lung Cancer. *Int J Radiat Oncol Biol Phys* 2007 Mar 15; 67(4):995-1001.

49. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS: Phase III Trial of Fludarabine Plus Cyclophosphamide Compared with Fludarabine for Patients with Previously Untreated Chronic Lymphocytic Leukemia: US Intergroup Trial E2997. *J Clin Oncol* 2007 Mar 5; 25(7):793-798. Epub 2007 Feb 5.

50. Haddock M, Swaminathan R, Foster N, Hauge M, Martenson J, Camoriano J, Stella P, Tenglin R, Schaefer P, Moore D, Alberts S: Gemcitabine, Cisplatin, and Radiotherapy for Patients with Locally Advanced Pancreatic Adenocarcinoma: Results of the North Central Cancer Treatment Group Phase II Study N9942. *J Clin Oncol* 2007 Jun; 25(18):2567-2572.

51. Jatoi A, Martenson JA, Foster NR, McLeod HL, Lair BS, Nichols F, Tschetter LK, Moore DF Jr, Fitch TR, Alberts SR: Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Preliminary Pharmacologic and Molecular Efforts to Mitigate Toxicity and

Predict Outcomes: North Central Cancer Treatment Group (N0044). *Am J Clin Oncol* 2007 Oct; 30(5):507-513.

52. Jatoi A, Dakhil SR, Foster NR, Ma C, Rowland KM Jr, Moore DF Jr, Jaslowski AJ, Thomas SP, Hauge MD, Flynn PJ, Stella PJ, Alberts SR: Bortezomib, Paclitaxel, and Carboplatin as a First-Line Regimen for Patients with Metastatic Esophageal, Gastric, and Gastroesophageal Cancer: Phase II Results from the North Central Cancer Treatment Group (N044B). *J Thorac Oncol* 2008 May; 3(5):516-520.

53. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB: Salvage Chemotherapy with Rituximab DHAP for Relapsed Non-Hodgkin Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. *Leuk Lymphoma* 2008 Jun; 49(6):1074-1080.

54. El-Osta HE, Yammine YS, Chehab BM, Fields AS, Moore DF, Mattar BI: Unexplained Hemopercardium as Presenting Feature of Primary Cardiac Angiosarcoma: A Case Report and a Review of the Diagnostic Dilemma. *J Thorac Oncol* 2008 Jul; 3(7):800-802.

55. Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Rowland KM, Bernath AM, Fitch TR, Soori G, Jett JR, Adjei AA, Perez EA: Phase III Randomized, Double-Blind Study of Maintenance CAI or Placebo in Patients with Advanced Non-Small Cell Lung Cancer after Completion of Initial Therapy (NCCTG 97-24-51). *Lung Cancer* 2008; 60(2): 200-207.

56. Inwards DJ, Fishkin PAS, Hillman DW, Brown DW, Ansell SM, Kurtin PJ, Fonseca R, Morton RF, Moore DF, Veeder MH, Stella PJ, Nikcevich DA, Wender DB, Fitch TR, Witzig TE: Long-Term Results of the Treatment of Patients with Mantle Cell Lymphoma with Cladribine (2-CDA) Alone (95-80-53) or 2-CDA and Rituximab (N0189) in the North Central Cancer Treatment Group. *Cancer* 2008; 113:108-116.

57. Ansell SM, Inwards DJ, Rowland KM, Flynn PJ, Morton RF, Moore DF, Kaufmann SH, Ghobrial IM, Kurtin PJ, Mauer M, Allmer C, Witzig TE: Low-Dose, Single-Agent Temsirolimus for Relapsed Mantle Cell Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. *Cancer* 2008 Aug; 113(3):508-514.

58. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer BW, Giannini C, Flynn PJ, Moore DF, Zweibel J, Buckner JC: Phase II trial of Vorinostat (SAHA) in Recurrent Glioblastoma Multiforme: a North Central Cancer Treatment Group Study. *J Clin Oncol* 2009 Apr 23; 27(12):2052-2058. Epub 2009 Mar 23.

59. Le Q, Moon J, Redman M, Williamson SK, Lara PN, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF, Gandara DR: Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer: SWOG 0222. *J Clin Oncol* 2009 June 13; 27(18):3014–3019. Epub 2009 Apr 13.

60. Horn L, Dahlberg S, Sandler A, Dowlati A, Moore DF, Murren JR, Schiller JH: Phase II Study of Cisplatin Plus Etoposide and Bevacizumab for Previously Untreated, Extensive-Stage Small-Cell Lung Cancer: Eastern Cooperative Oncology Group Study E3501. *J Clin Oncol* 2009 Dec 13; 27(35):6006-6011. Epub 2009 Oct 13.

61. Purnell JQ, Palesh O, Heckler C, Adams MJ, Chin N, Peppone L, Mohile S, Atkins JN, Moore DF, Spiegel D, Morrow GR: Prostate Cancer, Traumatic Stress, and Race: Secondary Analysis of a National URCC CCOP Study of 329 Men. *Supportive Care in Cancer.* PubMed. 2010 April. DOI:10.1007/s00520-010-0880-3.

62. Zonder J, Crowley J, Hussein M, Bolejack V, Moore D, Whittenberger B, Abidi, Durie B, Barlogie B: Lenalidomide and High-Dose Dexamethasone Compared with Dexamethasone as Initial Therapy for

Multiple Myeloma: a Randomized Southwest Oncology Group Trial (S0232). *Blood* 2010 Dec 27; 116(26:5838-5841. Epub 2010 Sep 27.

63. Barton DL, Atherton PJ, Bauer BA, Moore DF Jr, Mattar BI, Lavasseur BI, Rowland KM Jr, Zon RT, Lelindqwister NA, Nagargoje GG, Morgenthaler TI, Sloan JA, Loprinzi CL: The Use of Valeriana Officinalis (Valerian) in Improving Sleep in Patients who are Undergoing Treatment for Cancer: A Phase III Randomized, Placebo-Controlled, Double-Blind Study (NCCTG Trial, N01C5). *J Support Oncol* 2011 Jan-Feb; 9(1):24-31.

64. Loprinzi CL, Balcueva EP, Liu H, Sloan JA, Kottschade LA, Stella PJ, Carlson MD, Moore DF Jr, Zon RT, Levitt R, Jaslowski AJ. A Phase III Randomized, Double-Blind, Pacebo-Controlled Study of Pilocarpine for Vaginal Dryness: North Central Cancer Treatment group study N04CA. *J Support Oncol* 2011 May-Jun; 9(3):105-112.

65. Weroha SJ, Oberg AL, Ziegler KL, Dakhil SR, Rowland KM, Hartmann LC, Moore DF Jr, Keeney GL, Peethambaram PP, Haluska P: Phase II Trial of Lapatinib and Topotecan (Laptop) in Patients with Platinum-Refractory/Resistant Ovarian and Primary Peritoneal Carcinoma. *Gynecol Oncol.* 2011 July 22; 122(1):116-120. Epub 2011 Apr 22.

66. Purnell J, Palesh O, Heckler C, Adams M, Chin N, Mohile S, Peppone L, Atkins J, Moore D, Spiegel D, Messing E, Morrow G: Racial Disparities in Traumatic Stress in Prostate Cancer Patients: Secondary Analysis of a National URCC CCOP Study of 317 Men. *Support Care Cancer* 2011 Jul 23; 19(7):899-907. Epub 2010 Apr 23.

67. Jatoi A, Nieva JJ, Qin R, Loprinzi CL, Wos EJ, Novotny PJ, Moore DF Jr, Mowat RB, Bechar N, Pajon ER Jr, Hartmann LC: A Pilot Study of Long-Acting Octreotide for Symptomatic Malignant Ascites. *Oncology* 2012 10; 82(6):315-320. Epub 2012 May 10.

68. Loprinzi CL, Balcueva EP, Liu H, Sloan JA, Kottschade LA, Stella PJ, Soori GS, Moore DF, Zon RT, Steen PD, Jaslowski AJ: A phase III randomized, double blind, placebo-controlled study of pilocarpine for vaginal dryness: NCCTG study N04CA. *The Journal of Supportive Oncology.* Epub 2011 May 2. DOI: 10.1016/j.suponc.2011.02.005

69. Blumenthal DT, Rankin C, Stelzer KJ, Spence AM, Sloan AE, Moore DF Jr, Padula GDA, Schulman SB, Wade ML, Rushing EJ: A Phase III Study of Radiation Therapy (RT) and 06-Benzyl-Guanine (06-BG) Plus BCNU Versus RT and BCNU Alone and Methylation Status in Newly-Diagnosed Glioblastoma (GBM) and Gliosarcoma: Southwest Oncology Group (SWOG) Study S0001. *Intl J Clin Oncol* 2014 Nov 19. Epub 2014 Nov 19.

70. O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, Pitot HC, Shields AF, Landry JC, Ryan DP, Parda DS, Mohiuddin M, Arora A, Evans LS, Bahary N, Soori GS, Eakle J, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Wozniak TF, Roh MS, Yothers G, Wolmark N: Capecitabine and Oxaliplatin in the Preoperative Multimodality Treatment of Rectal Cancer: Surgical End Points From National Surgical Adjuvant Breast and Bowel Project Trial R-04. *J Clin Oncol.* 2014 June 5; 32(18):1927-1934. Epub 2014 May 5.

71. Lucas D, Ruppert A, Lozanski G, Dewald G, Lozanski A, Claus R, Plass C, Flinn I, Neuberg D, Paietta E, Bennett J, Jelinek D, Gribben J, Hussein M, Appelbaum F, Larson R, Moore D, Tallman M, Byrd J, Grever M: Cytogenetic Prioritization with Inclusion of Molecular Markers Predicts Outcome in Previously Untreated Patients with Chronic Lymphocytic Leukemia Treated with Fludarabine or Fludarabine Plus Cyclophosphamide: A Long-Term Follow-up Study of the US Intergroup Phase III Trial E2997. *Leuk Lymphoma* 2015 Mar 30:1-7. Epub 2015 Mar 30.

72. Rapp SR, Case LD, Peiffer A, Naughton MM, Chan MD, Stieber VW, Moore DF Jr, Falchuk SC, Piephoff JV, Edenfield WJ, Giguere JK, Loghin ME, Shaw EG: Donepezil for Irradiated Brain Tumor

Survivors: A Phase III Randomized Placebo-Controlled Clinical Trial. *J Clin Oncol.* 2015 May 20; 33(15):1653-1659. Epub 2015 April 20.

73. Steensma DP, Dakhil SR, Novotny PJ, Sloan JA, Johnson DB, Anderson DM, Mattar BI, Moore DF Jr, Nikcevich D, Loprinzi CL: A Randomized Comparison of Once Weekly Epoetin Alfa to Extended Schedule Epoetin or Darbepoetin in Chemotherapy-Associated Anemia. *Am J Hematol,* 2015 Jul 6. (Epub ahead of print).

74. Moore JA, Moore MB, Samaniego F, Pinnix CC, Moore DF Jr: Small Lymphocytic Lymphoma Presenting with Hypopituitarism. *Am J Med.* 2016 Jan; 129(1): e9-e10. Epub 2015 Sep 5.

75. Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, Shields AF, Landry JC, Ryan DP, Arora A, Evans LS, Bahary N, Soori G, Eakle JF, Robertson JM, Moore DF Jr, Mullane MR, Marchello BT, Ward PJ, Sharif S, Roh MS, Wolmark N: Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. *J Natl Cancer Inst.* 2015 Sep 14; 107(11). Erratum in *J Natl Cancer Inst.* 2016 Apr; 108(4).

76. Till BG, Li H, Bernstein SH, Fisher RI, Burack WR, Rimsza LM, Floyd JD, DaSilva MA, Moore DF Jr, Pozdnyakova O, Smith SM, LeBlanc M, Friedberg JW: Phase II Trial of R-CHOP plus Bortezomib Induction Therapy Followed by Bortezomib Maintenance for Newly Diagnosed Mantle Cell Lymphoma: SWOG S0601. *Br J Haematol.* 2016 Jan; 172(2): 208-218. Epub 2015 Oct 22.

77. Malhotra B, Rahal AK, Farhoud H, Moore DF Jr, Kallail KJ: Treatment of Recurrent Posttransplant Lymphoproliferative Disorder with Autologous Blood Stem Cell Transplant. *Case Rep Transplant.* 2015:801082. Epub 2015 Nov 25.

78. Peoples AR, Roscoe JA, Block RC, Heckler CE, Ryan JL, Mustian KM, Janelsins MC, Peppone LJ, Moore DF Jr, Coles C, Hoelzer KL, Morrow GR, Dozier AM. Nausea and disturbed sleep as predictors of cancer-related fatigue in breast cancer patients: a multicenter NCORP study. Support Care Cancer. 2017 Apr;25(4):1271-1278. doi: 10.1007/s00520-016-3520-8. Epub 2016 Dec 20. PubMed PMID: 27995318; PubMed Central PMCID: PMC5323277.

79. Witzig TE, Johnston PB, LaPlant BR, Kurtin PJ, Pederson LD, Moore DF Jr, Nabbout NH, Nikcevich DA, Rowland KM, Grothey A. Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU). Am J Hematol. 2017 Oct;92(10):1004-1010. doi: 10.1002/ajh.24824. Epub 2017 Aug 17.

80. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle K, Buckner JC, Ligon KL, Ballman KV, Moore DF Jr, Nebozhyn M, Loboda A, Schiff D, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Cerhan J, Giannini C, Wen PY. Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. Alliance for Clinical Trials in Oncology and ABTC. Neuro Oncol. 2018 Mar 27;20(4):546-556. doi: 10.1093/neuonc/nox161.

81. Algazi AP, Othus M, Daud AI, Lo RS, Mehnert JM, Truong TG, Conry R, Kendra K, Doolittle GC, Clark JI, Messino MJ, Moore DF Jr, Lao C, Faller BA, Govindarajan R, Harker-Murray A, Dreisbach L, Moon J, Grossmann KF, Ribas A. Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nat Med. 2020 Oct;26(10):1564-1568. doi: 10.1038/s41591-020-1060-8. Epub 2020 Oct 5. PMID: 33020646.

82. Jaoude DA, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF Jr. Glioblastoma and Increased Survival with Longer Chemotherapy Duration. Kans J Med. 2019;12(3):65-69. Published 2019 Aug 21.

83. Hearon BF, Redelman KN, Elhomsy GC, Moore DF Jr. Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy. Case Rep Oncol. 2020 Dec 14;13(3):1483-1489. doi: 10.1159/000512013. PMID: 33442373; PMCID: PMC7772860.

OTHER PUBLICATIONS: (letters to the author, book review, etc.)

1. Moore D, Cabanillas F: What Constitutes a Cure in Lymphoma? [Editorial] *Leuk Lymphoma* 1993 Oct; 11(304):161-163
2. Moore DR Jr, Buescher S, Vadhan-Raj S: Interleukin-1 Alpha Administration Increases Oral Granulocytes and Epithelial Cells. [Letter] *J Infect Dis* 1994; 169(6):1419-1420.
3. Moore DF Jr, Huber M, Lippman SM, Hagemeister FB: Merkel Cell Carcinoma as a Second Primary Tumor in a Patient with Non-Hodgkin's Lymphoma. *Cancer Bulletin* 1995; 47:175-177.
4. Moore DF Jr, Swan F, Yau J, Rodriguez MA, McLaughlin P, Sarris A, Romaguera J, Younes A, Hagemeister FB, Cabanillas F: Cyclosporine Plus Doxorubicin, Vincristine and Etoposide in the Treatment of Refractory Non-Hodgkin's Lymphoma: A Phase II Study. *Clin Oncol R Coll Radiol* 1995; 7(5):300-303.
5. Robbins WA, Meistrich ML, Moore D, Hagemeister FB, Weier HU, Cassel MJ, Wilson G, Eskenazi B, Wyrobek AJ: Chemotherapy Induces Transient Sex Chromosomal and Autosomal Aneuploidy in Human Sperm. *Nat Genet* 1997 May; 16:74-78. [Letter]

BOOKS AND BOOK CHAPTERS:

1. Moore DF Jr, Andreeff M: The acute leukemias, in Pazdur R (ed): *Medical Oncology: A Comprehensive Board Review.* Philadelphia (Huntington, NY), PRR Inc, 1993, pp 3-28.
2. Moore DF Jr, Mitsuyasu R: HIV-associated malignancies, in Pazdur R (ed): *Medical Oncology: A Comprehensive Board Review.* Philadelphia (Huntington, NY), PRR Inc, 1993, pp 379-393.
3. Moore DF Jr, Lee JS: Staging classification and prognostic factors for non-small cell lung carcinoma, in Pass HI, Mitchell J, Johnson DH, Turrisi AT (eds): *Lung Cancer: Principles and Practice*. Philadelphia, JB Lippincott, 1995, pp 481-495.
4. Moore DF Jr, Vadhan-Raj S: Hematopoietic growth factors in bone marrow failure states, in *Treatment of Radiation Injuries*. New York, Plenum Press.
5. Moore DF Jr, Lippman SM, Kalvakolanu DVR, Borden EC, Kavanagh JJ, Paredes-Espinoza M, Schleuniger U, Massimini G, Holdener E, Hong WK, Krakoff IH: Retinoic acid and interferon combination strategies in solid tumors: Rationale and results, in *Differentiation Therapy.* Rome, Serono Symposia Publications.
6. Moore DF Jr (ed): Clinicians' Guide to Lymphoma; PRR, Inc 1997.

PUBLISHED ABSTRACTS:

1. Moore D, Pazdur R, Daugherty K, Gutterman J, Levin B: A Phase I Study of 5-Fluorouracil with Folinic Acid Combined with Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor. *Proc Am Soc Clin Oncol* 1991; 10:1121 (#318).
2. Moore D, Estey E: Prognostic Value of the Day 14 Bone Marrow Examination in Newly Diagnosed Acute Myelogenous Leukemia. *Blood* 1991; 78(Suppl 1):457a (#1820).

3. Pazdur R, Gomez J, Schmidt S, Bready B, Moore D Jr, Light S, Mott D, Zhi J, Satoh H, Min B: Phase I Pharmacokinetic Study of Fluorouracil (FU) and Recombinant Alpha-2A Interferon (IFN). *Proc Am Soc Clin Oncol* 1993; 12:152a (#408).

4. Jaiyesimi I, Pazdur R, Ho DH, Lassere Y, Moore D Jr, Bready B, Krakoff IH: Phase I Trials of UFT (Ftorafur plus Uracil) and Leucovorin: 28 Day Schedule. *Proc Am Soc Clin Oncol* 1993; 12:152a (#409).

5. Bready B, Pazdur R, Sugarman S, Abbruzzesse J, Jones D, Moore D Jr: Phase II Study of Recombinant Alpha-2a Interferon and Isotretinoin in Patients with Advanced Colorectal Carcinoma. *Proc Am Soc Clin Oncol* 1993; 12:214a (#652).

6. Moore D Jr, Pazdur R, Bready B, Giannone L, Lin YG, Maldonado A, Winn R: Phase II Trial of Edatrexate in Advanced Hepatocellular Carcinoma. *Proc Am Soc Clin Oncol* 1993; 12:216a (#653).

7. Moore D Jr, Pazdur R, et al: UFT and High Dose Leucovorin Every 28 Days: A Phase I Study. *Proc Am Assoc Cancer Res* 1993; 34.

8. Moore D Jr, Swan F, Yau J, Rodriguez MA, McLaughlin P, Hagemeister F, Romaguera J, Katz RL, Huh YO, Sniege N, Redman JR, Velasquez WS, Grenko RT, Ordonez N, Cabanillas F: Cyclosporine Plus Doxorubicin, Vincristine, and VP-16 in the Treatment of Refractory Non-Hodgkin's Lymphoma: A Phase II Study. *Proc Am Soc Clin Oncol* 1994; 13:389 (#1325).

9. Younes A, Sarris A, McLaughlin P, Romaguera J, Jendiroba D, Swan F, Rodriguez A, Hagemeister F, Moore D, Cabanillas F: Phase II Trial of Taxol Given as 3-Hour Infusion Schedule Every 3 Weeks in Relapsed Non-Hodgkin's Lymphoma (NHL). *Proc Am Soc Clin Oncol* 1994; 13:374 (#1267).

10. Carrum G, Moore D, Hagemeister FB, Crow MK, Cabanillas F: Clinical Features and Outcome for Patients (Pts) 60 Years and Older with Hodgkin's Disease (HD). *Proc Am Soc Clin Oncol* 1994; 13:389 (#1324).

11. McLaughlin P, Hagemeister FB, Sarris A, Romaguera J, Pate O, Younes A, Swan F, Moore D, Cabanillas F: Fludarabine, Mitoxantrone, and Dexamethasone (FND) for Recurrent Low-Grade Lymphoma (LGL): A Phase II Trial. *Proc Am Soc Clin Oncol* 1994; 13:387 (#1318).

12. Moore D Jr, Pazdur RP, Sugarman S, Jones D III, Lippman SM, Bready B, Abbruzzesse JL: Pilot Phase II Trial of 13-Cis-Retinoic Acid and Interferon-Alpha in Advanced Pancreatic Adenocarcinoma. *Proc Am Soc Clin Oncol* 1995.

13. Moore DF Jr, Hagemeister FB: Clinical Characteristics and Outcome of Hodgkin's Disease in 125 Patients 60 Years of Age and Older. *Blood* 1994; 84 (Suppl 1):163a (#637).

14. Sarris AH, Younes A, McLaughlin P, Moore D, Hagemeister F, Swan F, Rodriguez MA, Romaguera J, North L, Cabanillas F: Cyclosporin A Does Not Reverse Clinical Resistance to Paclitaxel (Taxol) in Patients with Relapsed Non-Hodgkin's Lymphoma. *Blood* 1994; 84 (Suppl 1):167a (#654).

15. Romaguera JE, Sarris AH, Swan F Jr, Younes A, McLaughlin P, Rodriguez MA, Moore DF, Cabanillas F: Phase II Study of 5-Fluorouracil by Protracted Infusion in Patients with Relapsing or Refractory Lymphoma. *Blood* 1994; 84 (Suppl 1):647a (#2573).

16. Moore DF Jr, Moore DF Sr, Johnson DB, Cannon MW, Whisman SA, Church PS, Palko W, Dakhil S, Hynes HE: Bethesda Unit Titer as a Prognostic Factor for Patients with Acquired Factor VIII Inhibitors. *Blood* 1994; 84(Suppl 1):680a (#2705).

17. Moore DF Jr, Moore DF Sr, Diener C, Armstrong L, Slavik M, Watson E, Martin L, Peterson M: Efficacy of Granisetron (Kytril) for Chemotherapy-Associated Nausea and Vomiting in a VA Teaching Hospital. *Proc Am Soc Clin Oncol* 1995; 14:534 (#1762).

18. Hewitt St, Moore DF Jr: Black (Hairy) Tongue as an Indicator of Poor Outcome in Patients with Advanced Malignancy. *Proc Am Soc Clin Oncol* 1995; 14:498 (#1631).

19. Moore DF Jr, Moore DF Sr, Johnson DB, Bluml P, Cannon MW, Dakhil SR, Palko W, Hynes HE: Interleukin-2 (IL-2) Therapy Following Autologous Blood and Marrow Transplantation in Burkitt's Lymphoma: Effect on Lymphocyte Subsets. *Proc of Second Pan-Pacific Lymphoma Conference* 1995.

20. Wu J, Moore D Jr, Stobaugh J, Slavik M: Pharmacokinetic Modeling of Etoposide (VP-16) Administered by Short Intravenous Infusion. Fifth Annual Research Forum, University of Kansas School of Medicine-Wichita, Book of Abstracts 1995; 5:6.

21. Wu J, Svojanovsky S, Moore D Jr, Stobaugh J, Slavik M: Pharmacokinetic Modeling of Taxol Administered by Clinically Used Intravenous Infusional Schedules. Fifth Annual Research Forum, University of Kansas School of Medicine-Wichita, Book of Abstracts 1995; 5:8.

22. Lee BG, Moore DF Jr, Fleming RH: Response to Immunomodulation in a Patient with Cardiac Transplant Associated Non-Hodgkin's Lymphoma (NHL): Role of Lymphocyte Sub-Populations in Serial Reduction in Immunosuppression. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by E. Magana.

23. Nelson TL, Schulz TK, Moore DF Jr, Moore DF Sr, Hartman K, Rohlman V: Hemolytic Anemia Secondary to the Bite of a Brown Recluse Spider: Case Reports and a Review of the Literature. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by T. Nelson.

24. Ramsey TC, Moore DF Jr: Evaluation of Hemolytic Anemias. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by T. Ramsey.

25. Schmidt DR, Moore D Jr, Moore DF Sr, Kovach KL, Weber HP Jr: Severe Metabolic Acidosis Associated with the Therapeutic Use of Interleukin-2 in Non-Hodgkin's Lymphoma. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by D. Schmidt.

26. Moore DF Jr, Schmidt DR, Moore DF Sr, Kovach KL, Weber HP Jr: Severe Metabolic Acidosis Associated with the Therapeutic Use of Interleukin-2 in Non-Hodgkin's Lymphoma. *Blood* 1996; 88 (Suppl 1): (#3868).

27. Moore DF Jr, Preti A, Tran SM, Hagemeister FB, Rodriguez MA, McLaughlin P, Romaguera J, Sarris A, Younes A, Moore DF Sr, Cabanillas F: Prognostic Implications Following an Indeterminate Non-diagnostic Workup of Lymphoma. *Blood* 1996; 88(Suppl 1): (#906).

29. Chauncey TR, Rankin C, Anderson JE, Godwin JA, Kalaycio M, Moore DF, Petersdorf SH, Shurafa MS, Kraut EH, Head DR, Slovak ML, Willman CL, Appelbaum FR: A Phase I Dose-Finding Study of Induction Chemotherapy for Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Mitoxantrone (M), Etoposide (E), and the MDR Modulator PSC833: Southwest Oncology Group Study #9617. *Blood* 1998; 92(10) (Suppl. 1):231a (#945).

30. Morrow GR, JT Hickok, Lindke JL, Moore DF Jr., Wichita CCOP, Rousey S, Metro-Minnesota CCOP, Banerjee TK, Marshfield Medical Research Foundation CCOP, Wade P, Greater Phoenix CCIOP, University of Rochester Cancer Center, CCOP Research Base, Rochester NY: Longitudinal Assessment of Fatigue in Consecutive Chemotherapy Patients: A URCC CCOP Study. Proceedings of ASCO 1999; 18:593a (2293).

31. Aguayo A, Kraut EH, Moore DF, Wright JJ, Jones D, Winn R, Pazdur R: Phase II Study of Dolastatin 10 Administered Intravenously Every 21 Days to Patients with Metastatic Colorectal Cancer. American Society of Clinical Oncology (ASCO) Proceedings 2000; 19:288a (#1127).

32. Kelly K, Crowley J, Presant C, Grevstad P, Bunn P, Wozniak A, Weiss G, Moore D, Raghaven D, Livingston R, Gandara D: A randomized Phase III trial of Paclitaxel Plus Carboplatin Versus Vinorebine Plus Cisplatin in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer: A Southwest Oncology Group Trial. *J Clin Oncol* 2001 Jul 1; 19(13):3210-3218.

33. Saad ED, Kraut EH, Paula HM, Moore DF Jr, Jones D, Pazdur R, Abbruzzese JL: Phase II Study of Dolastatin-10 as First-Line Treatment for Advanced Colorectal Cancer. *Am J Clin Oncol* (CCT), 2002; 25(5).

34. Alberts SR, Townley PM, Cha S, Moore DF Jr, Krook JE, Fitch TR, Sargent DJ, Goldberg RM: Oxaliplatin and Gemcitabine for Patients with Pancreatic Adenocarcinoma: a NCCTG Phase II Study. *Proc of Am Soc Clin Oncol* 2002; 21:152a.

35. Ghabach BS, Moore DF Jr,: Glanzmann's Patient with Acute Intra-Abdominal Bleeding; Successful Use of Recombinant Factor VII. *Blood* 2003; 102:79b (#4024).

36. Ghabach BS, Moore DF, Jr,: Langerhans Cell Histiocytosis: A Variety of Clinical Presentations and Treatment Options. *Blood* 2003; 102:287b (#4869).

37. Ghabach BS, Moore DF, Jr: Waldenstrom Macroglobulinemia Presenting as a Gastric Mass. *Blood* 2003; 102:366b (#5191).

38. Roscoe JA, Morrow GR, Hickok JT, Bushunow P, Pierce HI, Flynn PJ, Kirshner JJ, Moore DF Jr., Atkins JN: The Efficacy of Acupressure and Acustimulation Wrist Bands for Chemotherapy-Induced Nausea and Vomiting: A University of Rochester Cancer Center CCOP. *J Pain and Symptom Management* 2003 August; 26 (#731).

39. Goyle KK, Moore DF Jr., Garrett C, Goyle V: Benign Metastasizing Leiomyomatosis. *Am J Clin Oncol* 2003 October; 25(5).

40. Hofman M, Roscoe JA, Hickok JT, Morrow GR, Moore DF, Wade JL, Fitch T: Impact of Information Sources on Expectation of Cancer Treatment Side Effects. A URCC CCOP Study. ASCO 12/15/03; Control/Tracking Number 04-AB-682-ASCO.

41. Witzig TE, Geyer SM, Salim M, Inwards DJ, Fonseca R, Kaufman SH, Kurtin PJ, Colgan JP, Call TG, Moore DF Jr: A Phase II Trial of the Rapamycin Analog CCI-779 in Previously Treated Mantle Cell Non-Hodgkin's Lymphoma: Interim Analysis of 18 Patients. *Blood* 2003; 102(11), (#2374).

42. Flinn IW, Kumm E, Grever MR, Neuberg D, Dewald GW, Bennett JM, Paietta EM, Appelbaum FR, Larson RA, Hussein MA, Moore DF, Tallman MS: Fludarabine and Cyclophosphamide Produces a Higher Complete Response Rate and More Durable Remissions than Fludarabine in Patients with Previously Untreated CLL: Intergroup Trial E2997. *Blood* 2004 (suppl 1) 104:139a (# 475).

43. Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Mailliard JA, Kahanic SP, Rao RM, Moore DF, Kozelsky TF, Jett JR: A Phase I/II NCCTG Trial of Escalating Doses of Twice Daily Thoracic Radiation Therapy (TRT) in Limited-Stage Small Cell Lung Cancer (LSCLC). *Proc Am Soc Clin Oncol* 23:16 (#7163), 661s, 2005.

44. Sandler A, Szwaric A, Dowlati A, Moore DF Jr, Schiller: A Phase II Study of Cisplatin Plus Etoposide Plus Bevacizumab for Previously Untreated Extensive Stage Small Cell Lung Cancer (E3501): A Trial of the Eastern Cooperative Oncology Group. *Proc Am Soc Clin Oncol* (#7564), 2007.

45. Galanis E, Jaeckle KA, Maurer J, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF Jr, Zwiebel JA, Buckner JC: N047B: NCCTG Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Recurrent Glioblastoma Multiforme (GBM). *Proc Am Soc Clin Oncol* (#2004), 2007.

46. Jatoi A, Martenson JA, Foster N, McLeod HL, Lair BS, Brindle JS, Nichols F, Tschetter LK, Moore DF,

Fitch TR, Alberts SR: Paclitaxel, Carboplatin, 5-Fluorouracil and Radiation for Locally Advanced Esophageal Cancer: Phase II Results of Pharmacologic and Molecular Efforts to Mitigate Toxicity and Predict Outcomes: NCCTG (N0044). *Am J Clin Oncol.* 2007 Oct; 30(5):507-13.

47. Micallef IN, Maurer MJ, Nikcevich D, Cannon M, Moore D, Kurtin P, Witzig TE: A Phase II Study of Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. *Proc Am Soc Clin Onc* 2008; 26 (May 20s) (#8500).

48. Purnell J, Morrow G, Roscoe J, Jean-Pierre P, Atkins JN, Moore DF, Kasper LM: Disruptions in Activities of Daily Living for African American Prostate Cancer Patients Compared to Whites. (Submitted to ASCO, 2008).

49. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB: Salvage Chemotherapy with Rituximab DHAP for Relapsed Non-Hodgkin Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group. *Leuk Lymphoma.* 2008 Jun; 49(6):1074-1080.

50. El-Osta HE, Yammine YS, Chehab BM, Fields AS, Moore DF Jr, Mattar BI: Unexplained Hemopericardium as a Presenting Feature of Primary Cardiac Angiosarcoma: A Case Report and a Review of the Diagnostic Dilemma. *J Thorac Oncol.* 2008 Jul; 3(7):800-802.

51. Micallef IN, Maurer M, Nikcevich DA, Cannon MW, Schaefer E, Moore DF, Kurtin, PJ, Witzig TE: Final Results Of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. *J Clin Oncol* 2009; 27(15s):(#8508).

52. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Hardwick JS, Reilly JF, Loboda A, Nebozhyn M, Fantin VR, Richon VM, Scheithauer B, Giannini C, Flynn PJ, Moore DF Jr, Zwiebel J, Buckner JC: Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. *J Clin Oncol.* 2009 Apr 20; 27(12):2052-2058. Epub 2009 Mar 23. Erratum in *J Clin Oncol.* 2009 Jul 1; 27(19):3262-3263.

53. Le QT, Moon J, Redman M, Williamson SK, Lara PN Jr, Goldberg Z, Gaspar LE, Crowley JJ, Moore DF Jr, Gandara DR: Phase II Study of Tirapazamine, Cisplatin, and Etoposide and Concurrent Thoracic Radiotherapy for Limited-Stage Small Cell Lung Cancer: SWOG 0222. *J Clin Oncol.* 2009 Jun 220; 27(18):3014-3019. Epub 2009 Apr 13.

54. Johnston PB, LaPlant B, Kurtin P, Habermann T, Moore DF, Nabbout N, Nikcevich DA, Rowland KM, Witzig TE: Salvage Chemotherapy with Rituximab, Oxaliplatin, Cytosine Arabinoside and Dexamethasone (ROAD) in Patients with Relapsed CD20+ Aggressive B-Cell Lymphoma. *J Clin Oncol* 2009; 27(15s):(#8556).

55. Kim G, Foster N, Salim M, Flynn P, Moore DF, Zon R, Mowat R, Wiesentfeld M, McCullough A, Alberts S. N064B: Randomized Phase II Trial of Panitumumab, Erlotinib and Gemcitabine Versus Erlotinib-Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma. ASCO poster discussion. *J Clin Oncol* 29:2011 (suppl. 4); (#238).

56. Abou-Jaoude D, Moore JA, Moore MB, Twumasi-Ankrah P, Ablah E, Moore DF: Glioblastoma and Increased Survival with Longer Chemotherapy Duration. *J Clin Oncol* 31, 2013 (suppl; abstr e13006)

57. Case D, Naughton J, Stieber VW, Bayer GK, Bilodeau PA, Moore DF, Falchuk SC, Needles BM, Piephoff J, Edenfield WJ, Giguere JK, Erickson N, Loghin ME, Shaw EG, Rapp SR: Quality of Life (QOL) and Cognitive Status Among Irradiated Brain Tumor Survivors Treated with Donepezil or Placebo. *J Clin Oncol* 31, 2013 (suppl; abstr 2051).

58. Reddy PS, Rahal AK, Kallail KJ, Moore DF, Truong PV, Mattar BI, Cannon MW, Nabbout NH, Page SJ, Truong QV, Dakhil C, Deutsch JM, Dakhil SR: The Application of Next-Generation Sequencing in the Community Clinical Oncology Setting. *J Clin Oncol.* 34, 2016 (suppl; abstr e23145).

59. Choucair K., Mattar B, Truong Q, Koeneke T, Truong P, Dakhil C, Cannon M, Page S, Deutsch J, Carlson E, Moore D, Nabbout N, Kallail KJ, Dakhil SR, Reddy PS. "Liquid biopsy: a promising gateway to implementing precision medicine and clinical trials; a community-based oncology practice experience." 2020 ASCO poster discussion.

60. Choucair K., Mattar B, Truong Q, Koeneke T, Truong P, Dakhil C, Cannon M, Page S, Deutsch J, Carlson E, Moore D, Nabbout N, Kallail KJ, Dakhil SR, Reddy PS. Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice. The Oncologist, Feb 19, 2022.

61. Choucair K, Page SJ, Mattar BI, et al. Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience [published online ahead of print, 2022 Nov 23]. *Clin Breast Cancer*. 2022;S1526-8209(22)00261-0. doi:10.1016/j.clbc.2022.11.005

62. Anas Alqam, Joud Zakhour, Wissam Karam, Ryan Ashkar, Hayrettin Okut, Shaker R. Dakhil, Christopher Dakhil, Bassam Ibrahim Mattar, Travis Lee Koeneke, Dennis Frederic Moore, Joseph A Moore, Phu Van Truong, Quoc Van Truong, Seth Joel Page, Pavan S. Reddy "Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer." *ASCO Publications, Journal of Clinical Oncology*, 42:16_suppl, e12518-e12518, May 29, 2024.

63. Bansal A, Stoffel EM, Lim R, Stanich PP, Patel SG, Burke CA, Hall MJ, Singh A, Boardman LA, Samadder NJ, Ballestar V, Muller C, Scott AJ, Benante KA, Xu Y, Eickhoff J, Hyun M, Zaborek J, Aquila L, Umar A, Szabo E, Della'Zanna G, Richmond E, Bengtson L, Schlom J, Donahue RN, Toney NJ, Horn LA, Palena C, Gulley JL, Samaddar S, Moore Jr DF, Sharma P, Madan R, Hurley KE, Soon-Shiong P, Gabitzsch E, Sender L, Brenner D, Schuetze S, Djuric Z, Barroilhet LM, Thompson P, Bauman J, Khan SA and Vilar E (2026) "Design and preliminary report of a randomized phase IIb clinical trial of multitargeted recombinant adenovirus 5 vaccines against CEA, MUC1, and brachyury (Tri-Ad5) and the IL-15 receptor superagonist nogapendekin alfa inbakicept in Lynch syndrome (TRIAD5-Plus): the first cross-network trial of the Cancer Prevention Clinical Trials Network (CP-CTNet)." *Front. Immunol. 17*:1809281. doi: 10.3389/fimmu.2026.1809281 May 18, 2026.

POSTER EXHIBITS:

1. Moore D Jr, Pazdur R, Bready B, Dubovsky D, Wade J III, Belt R, Winn R: Phase II trial of Edatrexate (10-EdAM) in Advanced Pancreatic Carcinoma. *Proc Am Assoc Cancer Res* 1993 May 20; 34 (#1202). [Poster presentation]; Orlando, FL

2. Moore D Jr, Andreeff M, Mahadevia R, Van N, Zhao S, Goodacre A, Jeha S, Vadhan-Raj S: Effects of the Fusion Protein PIXY321 on the Proliferation of Bone Marrow Cells in Patients with Diamond-Blackfan Anemia. *Blood* 1993 December 5; 82(Suppl 1):(#341). [Poster presentation]; St. Louis, MO.

3. Moore DF Jr, Van N, Andreeff M, Jeha S, Mahadevia R, Van N, Zhao S, Vadhan-Raj S: Effects of the Fusion Protein (PIXY321 on Proliferation of Bone Marrow (BM) Cells in BM Failure States. *Proc Am Soc Clin Oncol* 1994; 13:298 (#972). [Poster presentation].

4. Dakhil SR, Hynes HE, Cannon MW, Johnson DB, Moore DF Jr: G-CSF Plus Ciprofloxacin in the Prevention of Sepsis in Patients with Severe Neutropenia Related to Chemotherapy. *Blood* 1994; 84(Suppl 1): 24a (#83). [Poster presentation].

5. Witzig TE, Geyer SM, Salim M, Inwards DJ, Fonseca R, Kaufmann SH, Kurtin P, Colgan JP, Call TG, Moore, DF Jr, White WL: A Phase II Trial of the Rapamycin Analog CCI-799 in Previousley Treated Mantle Cell Non-Hodgkin's Lymphoma: Interim Analysis of 18 Patients. *Journal Am Soc of Hematology* 2003; 102 643a (#2374). [Poster Presentation] Session:545-II.

6. Purnell J, Morrow GR, Roscoe JA, Jean-Pierre P, Atkins JN, Moore Jr. DF, Kasper LM: Disruptions in Activities of Daily Living for African American Prostate Cancer Patients Compared to Whites. *Proc Am Soc Clin Oncol* 2008. [General Poster Presentation] Session #17G.

7. Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore Jr. DF, Kurtin P, Witzig TE: A Phase II Study of Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. *Proc Am Soc Clin Oncol* 2008; 26. Clinical Science Symposium #8500.

8. Micallef IN, Maurer MJ, Nikcevich DA, Cannon M, Moore Jr. DF, Kurtin P, Witzig TE: A Phase II Study of Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. International Lymphoma Conference, June 4-7, 2008, Palazzo Dei Congressi, Lugano, Switzerland.

9. Moore D Jr. Randomized Phase II trial of Panitumumab, Erlotinib and Gemcitabine Versus Erlotinib-Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma. *Am Clin Oncol* (29):152:2639 May 20, 2011:4036. [Poster presentation]

10. Stevens PL, Lenihan DJ, Ky B, Wameke CL, Johnson MM, Abramson VG, Mayer IA, Adams PT, Campbell MG, Cheema PS, Moore DF, Yeshwant C, Carver JR, Fisch M: Prediction and Early Detection of Anthracycline-Related Cardiotoxicity Using Cardiac Biomarkers. *J Clin Oncol* 32:5s, 2014 (suppl; #9644).

11. Ky B, Wameke CL, Lenihan DJ, Cheema PS, Moore DF, Campbell MG, Yeshwant C, Adams PT, Krone R, Carver JR, Nasta S, Svoboda J, Schuster SJ, Reddy NM, Patel SM, Rieber AG, Johnson MM, Fisch M: Clinical Risk Prediction in Anthracycline Cardiotoxicity. *J Clin Oncol* 32:5s, 2014 (suppl; #9624)

12. Galanis E, Anderson SK, Miller CR, Sarkaria JN, Jaeckle KA, Buckner JC, Ligon KL, Ballman KV, Moore DF, Ahluwalia MS, Lee EQ, Gerstner ER, Lesser GJ, Prados M, Grossman SA, Giannini C, Wen PY: Phase II Trial of Vorinostat (VOR) Combined with Temozolomide (TMZ) and Radiation Therapy (RT) for Newly Diagnosed Glioblastoma (GBM) (Alliance N0874/ABTC-0902). *J Clin Oncol* 32:5s, 2014 (suppl; #2030).

13. Choucair K., Mattar B, Truong Q, Koeneke T, Truong P, Dakhil C, Cannon M, Page S, Deutsch J, Carlson E, Moore D, Nabbout N, Kallail KJ, Dakhil SR, Reddy PS. Liquid Biopsy-based Precision Therapy in Patients with Advanced Solid Tumors: A Real-world Experience from a Community-based Oncology Practice. Presented at American Society of Clinical Oncology Annual Meeting. June, 2021.

ORAL PRESENTATIONS

1. Scientific papers presented at national and international meetings:

a. Oncology and Managed Care, Managed Care Symposium and Case Managers Meeting, Westin-Galleria Hotel, Houston, Texas: April 20, 1994.

b. Clinical Characteristics and Outcome of Hodgkin's Disease in 125 patients 60 years of Age and Older, December 1-3, 1994, the American Society of Hematology meeting in Nashville, Tennessee (poster).

c. Abdallah JG, Moore DF Jr, Minns GO: Enteric-Associated T-cell lymphoma (EATCL) as an Unusual Presentation of *Helicobacter pylori* Associate 'MALT' Lymphoma. Presented at the American College of Physicians Kansas Regional Meeting, September 8-9, 1995 in Wichita, Kansas by Dr. Abdallah.

d. Interleukin-2 (IL-2) Therapy Following Autologous Blood and Marrow Transplantation in Burkitt's Lymphoma: Effect of Lymphocyte Subsets, July 25-28, 1995, Second Pan-Pacific Lymphoma Conference, Kapalua, Hawaii (poster).

e. Tran SM, Moore DF Jr, Cabanillas F: Prognostic Implications Following an Indeterminate Non-diagnostic Workup of Lymphoma. Presented to the American College of Physicians Kansas Regional Meeting, September 6-7, 1996, Overland Park, Kansas by S. Tran.

f. Lee BG, Moore DF Jr, Fleming RH: Response to Immunomodulation in Patients with Cardiac Transplant Associated Non-Hodgkin's Lymphoma (NHL): Role of Lymphocyte Sub-Populations in Serial Reduction in Immunosuppression. Presented to the American College of Physicians Kansas Regional Meeting, September 5-6, 1997, Wichita, Kansas by E. Magana.

g. McKee JW, Moore DF Jr: Glioblastoma Multiforme: Is There Increased Incidence in Southwest Kansas? Presented to the American College of Physicians Kansas Regional Meeting, September 5-6, 1997, Wichita, Kansas by J. McKee, who won a second place award in the Residents competition.

h. Medgyesy D, Dakhil S, Moore D, Scalzo A, Hoff PM, Abburzzese J, Winn R, Pazdur R: A Phase II Trial of a 5-day Continuous Infusion of 9-Aminocamptothecin (9-AC) Weekly for 3 Weeks in Patients with Advanced Colorectal Carcinoma. Proceedings of the Tenth Annual NIC-EORTC Symposium on New Drugs in Cancer Therapy, June 16-19, 1998, Amsterdam.

i. Chauncey TR, Rankin C, Anderson JE, Godwin JA, Kalaycio M, Moore DF, Petersdorf SH, Shurafa MS, Kraut EH, Head DR, Slovak ML, Willman CL, Appelbaum FR: A Phase I Dose-Finding Study of Induction Chemotherapy for Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Mitoxantrone (M), Etoposide (E), and the MDR Modulator PSC833: Southwest Oncology Group Study #9617. Proceedings of American Society of Hematology Fortieth Annual Meeting, December 4-8, 1998, Miami Beach, Florida.

j. Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Moore DF, Zwiebel JA, Buckner JC, Galanis E: Results of a Phase II Trial of Vorinostat in Patients with Recurrent Glioblastoma: Evidence of Post-Treatment Histone Acetylation in Tumor Tissue and Pharmacokinetic Analysis: North Central Cancer Treatment Group (NCCTG) Study N047B. 6th International Congress on Targeted Therapies, August 24-26, 2007.

k. Barton, D, Moore D Jr, Sloan J, Stella P, Bauer B, Morgenthaler T: The Evaluation of Valeriana Officianlis to Enhance Sleep and Fatigue in Cancer Survivors: NCCTG Trial N01C5. Multinational Association of Supportive Care, June 26–28, 2009, Rome, Italy.

2. Scientific papers presented at local and regional meetings:

a. Neurocysticercosis, 4/90, Baylor College of Medicine City-Wide Infectious Disease.

b. Castleman's disease, 8/90, Baylor College of Medicine City-Wide Hematology.

c. Soft tissue sarcoma, 4/2/91, University of Texas M.D. Anderson Cancer Center Division of Medicine Grand Rounds.

d. Small round cell tumor, 6/6/91, University of Texas M.D. Anderson Cancer Center Division of Medicine Grand Rounds.

e. Fludarabine therapy and late opportunistic infections, 7/10/91, Baylor College of Medicine City-Wide Hematology.

f. Aplastic anemia, 7/17/91, Baylor College of Medicine City-Wide Hematology.

g. Sézary syndrome, cutaneous lymphomas, and review of HTLV-I as an etiologic agents, 9/91, Baylor College of Medicine City-Wide Hematology.

h. PNH/Ham's Test and Kit Ligand, Fall 1991, Baylor College of Medicine Hematology Case Conferences.

i. Hemolytic disease of the newborn and intrauterine transfusions, 11/13/91, Baylor College of Medicine City-Wide Hematology.

j. Pica in iron deficiency anemia: case report and review of the literature, 1/22/92, Baylor College of Medicine City-Wide Hematology.

k. An update on the acute leukemias, 7/20/92, St. Joseph Medical Center Grand Rounds.

l. AIDS-associated malignancies, 7/23/92, Veterans Administration Medical Center Grand Rounds.

m. Biomarkers in head and neck malignancies, 2/26/93, University of Texas M.D. Anderson Cancer Center Journal Club, Section of Head and Neck and Thoracic Medicine Oncology.

n. Phase II study of edatrexate (10-EdAM) in advanced pancreatic adenocarcinoma, 3/93, University of Texas M.D. Anderson Cancer Center Protocol Meeting.

o. PIXY321 in Diamond-Blackfan anemia, 12/1/93, Baylor College of Medicine City-Wide Hematology.

p. AIDS-associated malignancies, 6/10/94, Temple Veterans Administration Medical Center Grand Rounds (Texas).

q. Update on Lymphomas, 9/6/94, St. Francis Regional Medical Center Internal Medicine Grand Rounds.

r. Update on Lymphomas, 9/16/94, University of Kansas School of Medicine-Wichita Grand Rounds.

s. New Issues in Bone Marrow Transplant, 11/1/94, St. Francis Regional Medical Center Conference.

t. Colon Cancer, 3/27/95, St. Joseph Medical Center Conference.

u. Lymphoma, 4/24/95, St. Joseph Medical Center Conference.

v. Adjuvant Chemotherapy for Breast Cancer, 8/30/95, Via Christi Regional Medical Center-St. Francis Campus Conference.

w. Adjuvant Chemotherapy -- Current Issues, October 6, 1995, Twenty-seventh Annual J.H. Holt Memorial Academic Assembly-Via Christi Regional Medical Center-St. Francis Campus.

x. Panel Discussion: Use of Endoscopy vs Use of Radiology in GI/Colon Malignancies, October 6, 1995, Twenty-seventh Annual J.H. Holt Memorial Academic Assembly-Via Christi Regional Medical Center-St. Francis Campus.

y. Leukemia Update, October 24, 1995, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds.

z. Current Knowledge in Tumor Markers, 10/26/95, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds

aa. Lung Cancer: Evaluation and Prognosis, December 18, 1995, Columbia Wesley Medical Center Grand Rounds.

bb. Anemia, 3/3/97, Columbia Wesley Medical Center Geriatric Series.

cc. Lymphomas, April 22, 1997, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds.

dd. Update on Prostate Cancer Screening and Management, 9/6/97, American College of Physicians Kansas Chapter Meeting, Wichita, Kansas. (State-of-the-Art Lecture)

ee. Stem cell transplantation, 10/5/99, Via Christi Regional Medical Center-St. Francis Campus Grand Rounds.

ff. Lung cancer, 1/24/00, Wesley Medical Center Noon Conference.

Updated: 05/2026